These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 1826408)

  • 1. Plasmin generation and fibrin(ogen)olysis following desmopressin infusion.
    Takahashi H; Tatewaki W; Wada K; Niwano H; Hanano M; Shibata A
    Am J Hematol; 1991 Apr; 36(4):255-8. PubMed ID: 1826408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
    van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
    Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
    Dempfle CE; Argiriou S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
    Blood; 2000 Oct; 96(8):2793-802. PubMed ID: 11023513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay.
    Levi M; de Boer JP; Roem D; ten Cate JW; Hack CE
    Thromb Haemost; 1992 Jan; 67(1):111-6. PubMed ID: 1377412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
    Agnelli G; Iorio A; Parise P; Goldhaber SZ; Levine MN
    Blood Coagul Fibrinolysis; 1997 Jun; 8(4):216-22. PubMed ID: 9199818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The initiation of fibrinolysis in alpha 2-plasmin inhibitor deficient plasma. Role of fibrin.
    Ichinose A; Aoki N
    Thromb Res; 1986 Mar; 41(6):847-54. PubMed ID: 2939589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
    Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
    J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The kinetics of plasmin inhibition by aprotinin in vivo.
    Kang HM; Kalnoski MH; Frederick M; Chandler WL
    Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
    Rouy D; Anglés-Cano E
    Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma.
    Takahashi H; Koike T; Yoshida N; Kitahara O; Hanano M; Shibata A; Aoki N
    Am J Hematol; 1986 Oct; 23(2):153-66. PubMed ID: 2944378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
    Kojima T; Gando S; Morimoto Y; Mashio H; Goda Y; Kawahigashi H; Kemmotsu O
    Thromb Res; 2001 Dec; 104(5):301-7. PubMed ID: 11738071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
    Thorsen S; Müllertz S; Suenson E; Kok P
    Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
    Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
    Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss.
    Mastroroberto P; Chello M; Zofrea S; Marchese AR
    Eur J Cardiothorac Surg; 1995; 9(3):143-5. PubMed ID: 7540397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced fibrinolytic activity during the course of hemodialysis.
    Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
    Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of fibrinogenolysis in patients with closed head injury.
    Kushimoto S; Shibata Y; Yamamoto Y
    J Neurotrauma; 2003 Apr; 20(4):357-63. PubMed ID: 12866815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.